SALT LAKE CITY, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with Memorial Sloan ...
SALT LAKE CITY, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a series of ongoing research collaborations ...
Hosted on MSN
Novel genomic screening tool enables precision reverse-engineering of genetic programming in cells
Collaborative research led by investigators at Dana-Farber/Boston Children's Cancer and Blood Disorders Center defines a novel approach to understanding how certain proteins called transcription ...
SALT LAKE CITY, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Japan’s Ministry of Health, Labour and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback